开发针对传染病和瘤病毒的mRNA疫苗的前景和挑战
Lakshmi Venkata Simhachalam Kutikuppala1, Islam Kourampi2, Ramya S D Kanagala3
1Department of General Surgery, Dr. YSR University of Health Sciences, Vijayawada 520008, India.
Medical sciences (Basel, Switzerland)
|May 28, 2024
概括
使者RNA (mRNA) 疫苗提供了一种快速和多功能平台来对抗疾病和癌症. 虽然有效,但mRNA不稳定性和传递方面的挑战需要进一步研究以获得最佳的存储和效率.
科学领域:
- 疫苗学和生物技术
- 分子生物学和免疫学 分子生物学和免疫学
背景情况:
- 使者RNA (mRNA) 疫苗代表了疫苗技术的重大进步,提供了一种多功能和快速的方法.
- 它们在打击传染病 (包括COVID-19) 和病毒引起的癌症方面的作用越来越得到认可.
- 尽管它们取得了成功,但不稳定性和退化等局限性影响了储存,交付和整体效率.
研究的目的:
- 突出mRNA疫苗技术在疫苗学中的变革潜力.
- 讨论mRNA疫苗在预防传染病和癌症方面的机制和应用.
- 为了解决mRNA疫苗平台目前的局限性和未来的研究方向.
主要方法:
- mRNA疫苗使用单链基因序列来指示宿主细胞产生特定的蛋白质.
- 这些蛋白质引起免疫反应,准备免疫系统对抗病原体或癌细胞.
- 交付通常涉及封装在像脂质纳米颗粒 (LNP) 等系统中,通过内细胞分裂进入细胞.
主要成果:
- 在临床试验中,mRNA疫苗的有效率高 (94-95%),特别是在COVID-19疫苗中.
- 这项技术可以快速适应疫苗设计,以应对不断变化的病毒基因组.
- 目前的mRNA疫苗提供了显著的安全性和保护,目前正在进行研究以确定免疫力持续时间.
结论:
- 对于开发新一代针对传染病和癌症的疫苗,mRNA疫苗技术具有巨大的潜力.
- 解决稳定性和交付方面的挑战对于优化它们的效率和广泛应用至关重要.
- 进一步的临床研究对于充分了解mRNA疫苗的长期保护作用和潜力至关重要.
相关概念视频
Rous Sarcoma Virus (RSV) and Cancer
5.1K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
5.1K
Leaky Scanning
5.1K
During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA. Marilyn Kozak discovered that the sequence RCCAUGG (where R...
5.1K
Initiation of Translation
32.6K
Initiating translation is complex because it involves multiple molecules. Initiator tRNA, ribosomal subunits, and eukaryotic initiation factors (eIFs) are all required to assemble on the initiation codon of mRNA. This process consists of several steps that are mediated by different eIFs.
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
32.6K
Nuclear Export of mRNA
7.7K
Before mRNAs are exported to the cytoplasm, it is crucial to check each mRNA for structural and functional integrity. Eukaryotic cells use several different mechanisms, collectively known as mRNA surveillance, to look for irregularities in mRNAs. Irregular or aberrant mRNA are rapidly degraded by various enzymes. If a defective mRNA escapes the surveillance, it would be translated into a protein which would either be non-functional or not function properly. One of the primary irregularities in...
7.7K
Cancer Vaccines
355
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
355
Viral Mutations
32.3K
A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
32.3K


